Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Granulab is a Malaysian medical device company that specializes in the development and production of synthetic bone graft substitutes. As a subsidiary of KPJ Healthcare Berhad, the company is a pioneer in the Malaysian biotechnology sector, being the first to manufacture locally developed synthetic bone grafts. Its flagship product, GranuMaS, is a bioactive calcium phosphate-based material designed for use in orthopedic, dental, and neurosurgical applications to repair bone defects. The company's products are engineered to be biocompatible and osteoconductive, providing a scaffold for new bone growth without the immunological risks of allografts. Granulab operates a certified manufacturing facility in Selangor and maintains rigorous quality standards, including ISO 13485 certification.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Granulab.